ALNA stock is trading at $0.075 in the pre-market on NASDAQ as heavy volume of 252,311,606 shares signals unusually active trading. The stock is up 3.16% versus the previous close of $0.0727, with a pre-market range between $0.06 and $0.1459. Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) is a U.S. biotechnology company focused on oral enzyme therapeutics, led by its ALLN-346 program for gout in chronic kidney disease. We summarize why ALNA stock is one of the most active names this pre-market and what traders should watch next.

ALNA stock: Pre-market price action and volume

ALNA stock opened pre-market at $0.0641 and shows a current quote of $0.075. Volume is 252,311,606 versus typical data feeds that show no reliable average volume, making today’s flow noteworthy. One clear signal: the intraday high today reached $0.1459, creating wide intraday volatility for short-term traders.

ALNA stock: Fundamental snapshot and key metrics

Allena Pharmaceuticals lists under the Healthcare sector, Biotechnology industry, with headquarters in Newton, Massachusetts. Latest fundamentals show EPS -0.638, a negative PE of approximately -0.12, cash per share $0.92, and book value per share $0.58, which underline a cash-backed small-cap biotech profile. Reported market cap data in the feed is 0 (not reported), so investors should verify market capitalization on exchange filings before sizing positions.

ALNA stock: Technical, liquidity and volatility signals

The intraday range from $0.06 to $0.1459 points to high volatility for ALNA stock in pre-market. Current ratio and cash coverage metrics are reasonable for a clinical-stage biotech, with current ratio 2.11 and cash ratio 1.91, supporting short-term liquidity. Large volume in an otherwise thinly traded microcap can produce rapid price swings and wide bid-ask spreads.

ALNA stock: Meyka AI grade and model forecast

Meyka AI rates ALNA with a score out of 100: 62.67 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 comparison, sector and industry performance, financial growth, key metrics, forecasts, analyst consensus, and fundamentals. Meyka AI’s forecast model projects a near-term reference target of $0.12 versus the current price $0.075, implying an implied upside of 60.00%. Forecasts are model-based projections and not guarantees.

ALNA stock: Catalysts, risks and upcoming events

Primary catalyst is clinical progress and regulatory updates for ALLN-346; any positive trial or partnership news could drive renewed buying. Key risks include negative operating earnings (net income per share -1.03), limited recent earnings announcements, and thin public float data. The company last listed an earnings announcement in 2022; investors should monitor SEC filings and company press releases for timing updates.

ALNA stock: Trading strategy for most-active session

For most-active traders, treat ALNA stock as high-volatility microcap: use tight risk controls and small position sizing. Consider a conservative short-term price target range: downside support $0.05 and a tactical upside target $0.15, with stop-losses sized to limit capital at risk. Check order book depth and confirm liquidity on NASDAQ before executing large orders. For research follow-ups, see company site and market pages on Meyka AI: https://meyka.ai/stocks/ALNA.

Final Thoughts

ALNA stock is one of the most active names in this pre-market session on NASDAQ, trading at $0.075 with 252,311,606 shares exchanging hands and an intraday high of $0.1459. The stock’s fundamentals show a clinical-stage biotech with negative EPS -0.638, solid short-term liquidity (current ratio 2.11) and limited public data on market cap. Meyka AI rates ALNA 62.67 (B, HOLD) and its forecast model projects $0.12, an implied 60.00% upside from $0.075; forecasts are model-based projections and not guarantees. Traders focused on most-active opportunities should weigh trial news and liquidity risk, use strict risk limits, and confirm filings directly with the company. Meyka AI provides this concise AI-powered market analysis platform snapshot to help prioritize follow-up research and trade planning.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.